Cargando…

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients

BACKGROUND: The analysis of circulating free tumour DNA (ctDNA) in blood, commonly referred as liquid biopsy, is being used to characterise patients with solid cancers. Tumour-specific genetic variants can also be present in DNA isolated from other body fluids, such as urine. Unlike blood, urine sam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crisafulli, Giovanni, Mussolin, Benedetta, Cassingena, Andrea, Montone, Monica, Bartolini, Alice, Barault, Ludovic, Martinetti, Antonia, Morano, Federica, Pietrantonio, Filippo, Sartore-Bianchi, Andrea, Siena, Salvatore, Di Nicolantonio, Federica, Marsoni, Silvia, Bardelli, Alberto, Siravegna, Giulia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001107/ https://www.ncbi.nlm.nih.gov/pubmed/32149725 http://dx.doi.org/10.1136/esmoopen-2019-000572

Ejemplares similares

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
por: Crisafulli, Giovanni, et al.
Publicado: (2022)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
por: Russo, Mariangela, et al.
Publicado: (2018)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2009)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
por: Mauri, Gianluca, et al.
Publicado: (2021)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
por: Siravegna, Giulia, et al.
Publicado: (2017)

Early‐onset colorectal cancer in young individuals
por: Mauri, Gianluca, et al.
Publicado: (2018)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

Evolving neoantigen profiles in colorectal cancers with DNA repair defects
por: Rospo, Giuseppe, et al.
Publicado: (2019)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
por: Amodio, Vito, et al.
Publicado: (2023)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
por: Durinikova, Erika, et al.
Publicado: (2022)

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
por: Lorenzato, Annalisa, et al.
Publicado: (2020)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment
por: Amatu, Alessio, et al.
Publicado: (2022)

Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
por: Siravegna, Giulia, et al.
Publicado: (2014)

Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
por: Crisafulli, Giovanni, et al.
Publicado: (2023)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases
por: Giannini, Valentina, et al.
Publicado: (2022)

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Exploiting DNA repair defects in colorectal cancer
por: Reilly, Nicole M., et al.
Publicado: (2019)

A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
por: Russo, Mariangela, et al.
Publicado: (2022)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer
por: Moutinho, Catia, et al.
Publicado: (2013)

The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review
por: Lombardo, Roberta, et al.
Publicado: (2020)

Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases
por: Rizzetto, Francesco, et al.
Publicado: (2020)

Birthweight, Maternal Weight Trajectories and Global DNA Methylation of LINE-1 Repetitive Elements
por: Michels, Karin B., et al.
Publicado: (2011)

Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours
por: Bertero, L., et al.
Publicado: (2019)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i7hgit5b2dsdc6g3la2suo60gv